Navigation Links
CryoLife Conducts Surgeons Cardiac Allograft Symposium

ATLANTA, April 24 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is conducting the 2008 Cardiac Allograft Symposium at its corporate headquarters training facility in suburban Atlanta, GA, April 25-26. The program will focus on current clinical outcomes, indications and surgical techniques of aortic valve replacement utilizing aortic allografts and the CryoValve(R) SG pulmonary human heart valves.

"As leaders in human tissue transplantation and cardiac reconstruction, it is both an honor and a privilege to host this advanced surgical training at our state-of-the-art facility and laboratory," said Steven G. Anderson, president and chief executive officer of CryoLife, Inc. "We look forward to bringing together this eminent group of cardiovascular surgeons and offering them the opportunity to learn the newest surgical techniques utilizing human aortic valves and our recently FDA-cleared CryoValve SG pulmonary valve."

The symposium's distinguished faculty includes: John W. Brown, M.D., professor of cardiothoracic surgery, Indiana University School of Medicine, Indianapolis, Ind; Paul E. Stelzer, M.D., senior faculty, cardiothoracic surgery, Mount Sinai School of Medicine, New York, N.Y.; Craig R. Saunders, M.D., chairman of cardiothoracic surgery, Saint Barnabas Health Care System, Newark, N.J.; Kent E. Ward, M.D., associate professor of pediatric cardiology, University of Oklahoma Health Sciences Center, Oklahoma City, Okla; Kenton J. Zehr, M.D., professor of surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.; and Edward Nowicki, M.D., assistant head, clinical investigations, Heart & Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

The program director is William F. Northrup, III, M.D., vice president, medical relations and education at CryoLife. Steven Goldstein, Ph.D., senior director, tissue technologies at CryoLife is also on the faculty. Some 20 surgeons from around the United States are expected to participate in the symposium.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. Beginning May 1, 2008 CryoLife will distribute Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site:

Media Contacts:

D. Ashley Lee Katie Brazel

Executive Vice President, Fleishman Hillard

Chief Financial Officer and Phone: 404-739-0150

Chief Operating Officer

Phone: 770-419-3355

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife to Distribute FDA-approved Hemostatic Agent Under Private Label
2. CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services
3. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
4. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
5. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
6. CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
7. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
8. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
9. CryoLife Announces Record Preservation Services and Product Revenues for 2007
10. CryoLife to Present at OneMedPlace Finance Forum
11. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
Post Your Comments:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") ( ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):